Connect with us

Business

Traders Buzz: Seadrill Ltd(NYSE:SDRL), Linn Energy LLC (NASDAQ:LINE), Denbury Resources Inc. (NYSE:DNR)

Published

on

Lakeway, NY — (US MARKET BUZZ) — 12/17/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Seadrill Ltd(NYSE:SDRL), Linn Energy LLC (NASDAQ:LINE), Denbury Resources Inc. (NYSE:DNR).

Seadrill Ltd(NYSE:SDRL) shares jumped 4.22% to $11.10. Shareholder rights law firm Robbins Arroyo LLP on Dec. 10 announces that an investor of Seadrill Limited (SDRL) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between July 10, 2014 and November 25, 2014. Seadrill is the world’s largest offshore drilling contractor, providing offshore drilling services to the oil and gas industry worldwide. According to the complaint, Seadrill American Depository Receipts (“ADRs”) fell $5.52 per ADR, to close at $15.19 per ADR on November 26, 2014, after Seadrill revealed that it would be indefinitely suspending its $4 per share annual dividend.

Should Investors Buy SDRL After The Recent Development? Find Out Here

Linn Energy LLC (NASDAQ:LINE)’s shares gained 10.07% to $10.84. LINN Energy, LLC (LINE) (“LINN” or the “Company”) and LinnCo, LLC (LNCO) (“LinnCo”) on Dec. 15 announced that LINN has closed the previously announced sale of its entire position in the Granite Wash and Cleveland plays located in the Texas Panhandle and western Oklahoma to privately held institutional affiliates of EnerVest, Ltd. and FourPoint Energy, LLC at a contract price of $1.95 billion (the “Granite Wash sale”), subject to pre- and post-closing purchase price adjustments.

Is LINE Going To Rise or Fall After Today’s Price Action? Find Out Here

Denbury Resources Inc. (NYSE:DNR)’s shares gained 1.58% to $6.44. The company on Dec. 10 announced that it has entered into a new five-year revolving credit facility which amends and restates the Company’s prior facility that was set to mature in May 2016. This new amended and restated revolving credit facility (“Facility”) has a maximum facility size of $3.5 billion and an initial borrowing base of $3 billion. The Company elected to maintain the aggregate lender commitments at $1.6 billion to be consistent with the Company’s prior facility. The Facility provides for an annual redetermination of the borrowing base around May 1 of each year and permits the Company to increase the aggregate lender commitments up to the borrowing base amount with approval and incremental commitments from the existing lenders or new lenders.

Can Traders Buy DNR After The Solid Rally? Get Free Trend Analysis Here

About thenextbigtrade.com

thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.

Disclaimer

The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading

Business

Chesapeake Energy Corporation (CHK), Best Buy Co., Inc. (BBY) Are Top Early-Market Movers

Published

on

By

Shares of Chesapeake Energy Corporation (CHK) shot up 8% in first hour Wednesday, after the oil and gas production company reported fourth-quarter earnings and revenue that beat expectations, and provided an upbeat outlook. Net income rose to $486 million, or 49 cents a share, from $309 million, or 33 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS fell to 21 cents from 30 cents but beat the FactSet consensus of 18 cents.

Total revenue rose 22% to $3.07 billion, as oil, natural gas and natural-gas equivalent revenue jumped 38% to $1.73 billion. The FactSet consensus for total sales was $2.28 billion for oil and gas sales was $1.10 billion. Average daily production fell 7% to 464,000 barrels of oil equivalent (BOE) while production expenses increased 15% to $2.87 BOE. The company projects 2019 average daily oil production to increase about 32%, capital expenditures are expected to be flat and cash flow is expected to be “meaningfully stronger.” The stock has lost 12% over the past three months through Tuesday, while the SPDR Energy Select Sector ETF has gained 1.5% and the S&P 500 has advanced 4.2%.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Best Buy Co., Inc. (BBY)jumped after the gadget retailer lent a spark to what had been a gloomy earnings season by delivering holiday sales that outpaced projections and a full-year profit outlook that topped analysts’ estimates.

Comparable-store sales in the U.S. — the retailer’s most-watched metric — rose 3 percent in the fourth quarter, beating projections. The midpoint of its profit forecast for the current fiscal year also topped estimates, sending the shares up as much as 16 percent.

The shares climbed as high as $69.85 in New York Wednesday, the biggest intraday gain since May 2017. The shares had already been up 14 percent this year through Tuesday’s close, outpacing the S&P 500 Index.

ASDN could be a potential acquisition target for Uber as it develops its patents and tech for the long awaited Uber Air

Continue Reading
Advertisement

Trending